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bjectives This study sought to evaluate second-generation drug-eluting stent (DES) thrombosis in
linical practice.
ackground First-generation DES are associated with a signiﬁcant incidence of late thrombosis. There is
aucity of data regarding real practice late thrombosis incidence and predictors with second-generation
ES, zotarolimus-eluting stent (ZES), and everolimus-eluting stents (EES).
ethods A prospective, large-scale, non-industry-linked multicenter registry was designed. Complete
linical-procedural data and systematic follow-up of all patients treated with these stents was reported in
dedicated registry supported by the Spanish Working Group on Interventional Cardiology.
esults From 2005 to 2008, 4,768 patients were included in 34 centers: 2,549 treated with ZES, and
,219 with EES. The cumulative incidence of deﬁnite/probable thrombosis for ZES was 1.3% at 1 year
nd 1.7% at 2 years and for EES 1.4% at 1 year and 1.7% at 2 years (p  0.8). The increment of deﬁnite
hrombosis between the ﬁrst and second year was 0.2% and 0.25%, respectively. In a propensity score
nalysis, the incidence remained very similar. Ejection fraction (adjusted hazard ratio [HR]: 0.97; 95% con-
dence interval [CI]: 0.95 to -0.99; p  0.008), stent diameter (adjusted HR: 0.37; 95% CI: 0.17to 0.81;
 0.01) and bifurcations (adjusted HR: 2.1; 95% CI: 1.14 to 3.7; p  0.02) emerged as independent pre-
ictors of thrombosis. In the subgroup of patients with bifurcations, the use of ZES was independently
ssociated with a higher thrombosis rate (adjusted HR: 4; 95% CI: 1.1 to 13; p  0.03).
onclusions In a real practice setting, the incidence of thrombosis at 2 years with ZES and EES was
ow and quite similar. The incidence of very late thrombosis resulted lower than was reported in registries
f ﬁrst-generation DES. In the subset of bifurcations, the use of ZES signiﬁcantly increased the risk of
hrombosis. (J Am Coll Cardiol Intv 2010;3:911–9) © 2010 by the American College of Cardiology Foundation
rom the *Interventional Cardiology Department, Unidad de Hemodina´mica y Cardiologı´a Intervencionista, Hospital Universi-
ario Marques de Valdecilla, Instituto de Formacio´n e Investigacio´n Marqués de Valdecilla, Santander, Spain; †Interventional
ardiology Department, Hospital Clı´nico San Carlos, Madrid, Spain; ‡Interventional Cardiology Department, Hospital de la
rincesa, Madrid, Spain; §Interventional Cardiology Department, Hospital Gregorio Maran˜on, Madrid, Spain; Interventional
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912rug-eluting stents (DES) have proved to be an outstand-
ng improvement in the interventional cardiology field.
heir known impact on restenosis rates drop in almost every
linical and lesional profile has expanded percutaneous
evascularization horizons. Nevertheless, both first-
eneration DES, paclitaxel-eluting stents (PES) and
irolimus-eluting stents (SES), have been associated with a
ertain incidence of late thrombosis in trials that was greater
han that observed with bare-metal stents (1). This incidence
as higher in real practice registries than in randomized trials
ue to a frequent off-label use of these DES (2–6).
Thrombosis of first-generation DES may occur up to 4
ears after implantation, with an increment after the first
ear of 0.4% to 0.6% per year. Second-generation DES,
otarolimus-eluting stents (ZES) and everolimus-eluting
tents (EES), are already available. They have already been
valuated in different clinical trials (7–14) and have shown
n most of them a similar if not better safety profile than
rst-generation DES (7,8,10–13), but worse results have
een also reported (9,14). However, once again, large
independent registries, with
long-term follow-up, are needed
in order to assess late thrombosis
incidence in the real-world clinical
practice.
Methods
The ESTROFA-2 (Estudio Es-
pan˜ol Sobre Trombosis de
Stents Farmacoactivos de Seg-
unda Generacion-2) registry is
an independent, multicenter,
and prospective registry run by a
research hospital network” designed to assess DES throm-
osis incidence in real practice. A total of 34 centers all
round Spain have been involved. Economic costs and
aintenance of the Web-based electronic clinical research
orum were held thanks to the support given by the Spanish
orking Group on Interventional Cardiology. All coordi-
ation between the 34 participating centers, the adjudica-
ion process, and analyses have been performed centrally at
he coordination center Hospital Universitario Marques de
aldecilla in Santander, Spain.
ardiology Department, Hospital La Paz, Madrid, Spain; ¶Interventional Cardiology
epartment, Hospital 12 de Octubre, Madrid, Spain; #Interventional Cardiology
epartment, Hospital Clinico de Valladolid, Valladolid, Spain; **Interventional
ardiology Department, Hospital Miguel Servet, Zaragoza, Spain; ††Interventional
ardiology Department, Hospital San Juan de Alicante, Alicante, Spain; ‡‡Inter-
entional Cardiology Department, Hospital de Leo´n, Leo´n, Spain; §§Interventional
ardiology Department, Hospital Clinico de Valencia, Valencia, Spain;  Interven-
ional Cardiology Department, Policlı´nica Guipúzcoa, San Sebastian, Spain; ¶¶In-
erventional Cardiology Department, Hospital Juan Ramo´n Jiménez, Huelva, Spain;
bbreviations and
cronyms
ES  drug-eluting stent(s)
ES  everolimus-eluting
tent(s)
ES  paclitaxel-eluting
tent(s)
ES  sirolimus-eluting
tent(s)
ES  zotarolimus-eluting
tent(s)#Interventional Cardiology Department, Hospital Clinico de Salamanca,
alamanca, Spain; ***Interventional Cardiology Department, Hospital Son Dureta, Matient selection. All consecutive patients treated at the
articipating hospitals with either an EES or a ZES, since
heir introduction in the Spanish market in 2005 to 2006 up
o 2008, were prospectively entered in an electronic CRF.
or the cases to be considered for final analysis, all lesions
hould have been treated with EES or with ZES, with no
ix. Clinical, angiographic, and procedure features of every
ingle case were filled in by the local investigators. If a
hrombosis event was detected in the established follow-up
eriods, a wider detailed application form had to be com-
leted. Data collection met all national requirements re-
arding “data protection law” as well as anonymity.
eﬁnitions. All thrombosis recalled in this registry were
ndexed following the well-known Academic Research
onsortium definitions (15). Hyperlipidemia was defined as
lasmatic cholesterol greater than 200 mg/dl or previous
reatment with statins. Hypertension was defined as either
ystolic pressure greater than 140 mm Hg, or diastolic
ressure above 90 mm Hg or previous treatment with
ntihypertensive therapy. Renal function impairment was
onsidered for plasmatic creatinine above 1.5 mg/dl. An-
iographic success was defined as TIMI (Thrombolysis In
yocardial Infarction) flow grade 3 along with residual
tenosis below 25%.
linical follow-up. Information was obtained from medical
eports and hospital or interventional cardiology department
egistries. In those cases with no events reported in hospital
les and no recent outpatient clinical visit, phone contact
as required. All data regarding vital status, clinical events,
s well as new interventional procedures were, therefore,
pecifically collected for the purpose of this investigation.
onparticipant centers were contacted when necessary.
tatistical analysis. Continuous variables are presented as
ean  SD. Categorical variables are expressed as percent-
ges. Continuous variables were compared with the Student
test if the data followed a normal distribution and with
ilcoxon tests if the data were skewed. Categorical vari-
bles were compared with the chi-squared test or the
ischer exact test, where indicated. The survival curves were
onstructed with the use of Kaplan-Meier method to
escribe the incidence of thrombosis over time, and log rank
ests were applied to evaluate differences between groups.
Because patients were not randomized to EES or ZES,
ropensity scores (conditional probability) for receiving an
alma de Mallorca, Spain; †††Interventional Cardiology Department, Hospital
irgen de la Victoria, Malaga, Spain; ‡‡‡Interventional Cardiology Department,
ospital Carlos Haya, Malaga, Spain; §§§Interventional Cardiology Department,
ospital Germans Trias i Pujol, Badalona, Spain;   Interventional Cardiology
epartment, Hospital de Galdacano, Bilbao, Spain; ¶¶¶Interventional Cardiology
epartment, Hospital Vall d=Hebron, Barcelona, Spain; ###Interventional Cardiol-
gy Department, Hospital Meixoeiro, Vigo, Spain; ****Interventional Cardiology
epartment, Hospital Clinico de Tenerife, Santa Cruz de Tenerife, Spain; and the
†††Interventional Cardiology Department, Fundacio´n Alcorco´n, Alcorco´n, Spain.anuscript received June 8, 2010, accepted June 11, 2010.
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913ES rather than a ZES for each patient were calculated by
sing baseline covariates within a logistic regression model.
baseline model was defined and included the demo-
raphic, clinical, and procedural covariates listed in Table 1.
atients were then matched according to their individual
Figure 1. Thrombosis Incidence in Overall Population
Incidence of stent thrombosis: (A) deﬁnite stent thrombosis (p  0.6); (B) deﬁ
Table 1. Clinical and Procedural Characteristics
ZES
(n  2,549)
EES
(n  2,219) p Value
Age, yrs 66.8 11.8 66.2 11.5 0.07
Women 601 (23.6%) 535 (24.1%) 0.7
Current smoker 744 (29.2%) 604 (27.2%) 0.1
Diabetes 803 (31.5%) 806 (36.3%) 0.0005
HBP 1,529 (60%) 1,303 (58.7%) 0.37
Hypercholesterolemia 1,313 (51.5%) 1,197 (53.9%) 0.1
Renal failure 191 (7.5%) 155 (7%) 0.5
LVEF, % 56.4 12.0 56.5 13.0 0.9
Previous MI 479 (18.8%) 424 (19.1%) 0.8
Previous PCI 543 (21.3%) 548 (24.7%) 0.006
Previous CABG 160 (6.3%) 164 (7.4%) 0.1
ACS 1,922 (75.4%) 1,529 (68.9%) 0.0001
MI 670 (26.3%) 355 (16%) 0.0001
Lesions treated 1.44 0.8 1.47 0.76 0.1
Total stent length, mm 34.8 23 34.5 24 0.6
Stent diameter, mm 2.95 0.4 2.98 0.4 0.01
Dual therapy, months 11.3 1.9 11.6 1.5 0.001
Lesions n  3,670 n  3,261
Total occlusion 125 (3.4%) 127 (3.9%) 0.2
Restenosis 136 (3.7%) 202 (6.2%) 0.0001
Bifurcation 484 (13.2%) 470 (14.4%) 0.1
Calciﬁed 734 (20%) 668 (20.5%) 0.7
ACS acute coronary syndrome; CABG coronary artery bypass graft; EES everolimus-eluting
stents; HBP  high blood pressure; LVEF  left ventricular ejection fraction; MI  myocardial
infarction; PCI percutaneous coronary intervention; ZES zotarolimus-eluting stents.stent thrombosis (p  0.24). The blue lines are for the zotarolimus-eluting stent (ZEropensity scores. The individual propensity score as well as
ype of stent were incorporated into Cox proportional
azard regression models as a covariate to calculate the
ropensity adjusted hazard ratio (HR).
Identification of predictors of stent thrombosis was done
hrough a Cox proportional hazard regression model includ-
ng those variables with p  0.2 in the univariate analysis.
he variable of antiplatelet therapy discontinuation was not
ncluded because that information was not available for all
ases without stent thrombosis. Only the prescribed period
f dual therapy could be included in this analysis. All
robability values were 2-sided and values of p  0.05 were
onsidered statistically significant. The statistical package
PSS version 15.0 (SPSS, Inc., Chicago, Illinois) was used
hroughout.
esults
total of 4,768 patients were prospectively included in the
egistry; 2,549 of the patients were treated with ZES and
,219 with EES. As a rule, dual antiplatelet therapy was
rescribed for up to 12 months (only 6.4% of EES- and
0.6% of ZES-treated patients had dual antiplatelet therapy
rescribed for 6 months). Clinical and procedural features
re described in Table 1. The EES-treated patients were
lightly younger, more frequently diabetics, and had a
reater rate of previous interventions. ZES were more often
sed during an acute coronary syndrome. As for the
esional profile, more restenotic lesions were treated with
ES. Dual antiplatelet treatment recommended duration
as slightly shorter for the ZES group.
Thrombosis incidence (definite; definite and probable;
nd definite, probable, and possible) curves are displayed in
igure 1. Cumulative stent thrombosis incidence for both
probable stent thrombosis (p  0.8); (C) deﬁnite  probable  possiblenite 
S) data, and the brown lines are for everolimus-eluting stent (EES) data.
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914inds of stents is presented in Table 2. No statistically
ignificant difference was found between the 2 groups. The
ncrease in definite stent thrombosis incidence observed
rom the first to the second year was 0.2% to 0.25%.
Given the differences observed in the basal characteristics
f the 2 groups, a propensity score matching was performed.
ventually, 1,300 patients from each group were selected
nd compared. Clinical and procedural features are detailed
n Table 3. After adjusting, baseline characteristics were
dentical in the 2 groups. Cumulative stent thrombosis
ncidence curves for matched groups are presented in Figure
and incidences in Table 4. No difference in the incidence
f stent thrombosis was found after the matching process.
Definite and probable thrombosis predictors found in
nivariate and multivariate analysis are presented in Table 5.
nly bifurcations, ejection fraction, and stent diameter were
ound to be independent thrombosis predictors.
ntiplatelet treatment. Inappropriate withdrawal of anti-
hrombotic drugs was confirmed in up to 15% of definite
hrombosis and 7% of probable thrombosis. However, dual
ntiplatelet treatment prescription (12 months vs. 6 months)
as not found to be a predictor of stent thrombosis.
As previously described, there was a subgroup of patients
ith dual therapy indicated during 6 months. These pa-
ients were more frequently found in the ZES group. We
herefore decided to analyze stent thrombosis incidence only
n patients with antiplatelet dual treatment indicated for 12
onths. As presented in Figure 3A, no difference was noted
ither.
Differences in stent thrombosis incidence between pa-
ients with prescription for 6 months and those for 12
onths are shown in Figure 3B. This incidence tended to
e greater in the 6-month treated group although the
ifference was concentrated in the early period.
ubgroup analysis. Bifurcation-treated patients developed
ore cases of thrombosis (Fig. 4A). The use of complex
echniques (2 stents) tended to be higher among those cases
ith thrombosis (27.5% vs. 13.8%; p  0.06). The use of
he double stent treatment for bifurcations was comparable
n both stent groups (12.8% with EES and 14.9% with
ES; p  0.4). As is shown in Figure 4B, a greater stent
hrombosis rate was demonstrated in ZES-treated bifur-
Table 2. Cumulative Incidences of Stent Thrombosis
Definite Def.  Prob. Def.  Prob.  Poss.
ZES EES ZES EES ZES EES
1 month 0.4 0.3 0.8 0.7 0.8 0.7
1 yr 0.8 0.75 1.3 1.4 1.8 1.5
2 yrs 1.0 1.0 1.7 1.75 2.5 2.0
p 0.6 p 0.8 p 0.2
def definite; poss possible; prob probable; other abbreviations as in Table 1.ations. Bifurcation was the only lesion subset in whichtatistically significant differences in stent thrombosis
ere found between stent types (Fig. 5) in matched
roups. This difference was observed both in the early
nd late period. Age (adjusted HR: 1.06, 95% CI: 1.01 to
.12; p  0.04), ejection fraction (adjusted HR: 0.96,
5% confidence interval [CI]: 0.92 to 0.99; p  0.02),
nd ZES use (adjusted HR: 4, 95% CI: 1.1 to 13; p 
.03) were found to be independent thrombosis predic-
ors in bifurcation-treated patients. Based on our results,
he double stent technique was not an independent
redictor.
iscussion
irst-generation DES have proved to diminish the need for
ew revascularization in almost every clinical and lesional
etting leading to a spread in its use, even in off-label
ndications. Low late thrombosis rates obtained from clin-
cal trials have supported safety issues (1). Nevertheless, real
ractice registries frequently include off-label indications
nd have consistently revealed a higher late thrombosis rate
han bare-metal stents, with a 1.2% to 1.7% first-year
efinite thrombosis rate and a 0.4% to 0.6% late thrombosis
ate per year later on (2–6). Mechanisms involved in this
rocess could be lack of long-term endothelialization, pos-
tive arterial remodeling leading to late acquired incomplete
Table 3. Clinical and Procedural Characteristics in Propensity Score
Matched Groups
ZES
(n  1,300)
EES
(n  1,300) p Value
Age, yrs 67.4 11.2 67.3 11.3 0.8
Women 331 (25.5%) 315 (24.2%) 0.5
Current smoker 347 (26.7%) 346 (26.6%) 0.9
Diabetes 430 (33%) 440 (33.8%) 0.7
HBP 832 (64%) 822 (63.2%) 0.7
Hypercholesterolemia 706 (54.3%) 728 (56%) 0.4
Renal failure 105 (8.1%) 109 (8.4%) 0.8
LVEF, % 57.4 12 57.6 13 0.8
Previous MI 218 (16.8%) 221 (17%) 0.9
Previous PCI 222 (17%) 212 (16.3%) 0.6
Previous CABG 88 (6.8%) 92 (7%) 0.9
ACS 928 (71.4%) 914 (70.3%) 0.6
MI 177 (13.6%) 165 (12.7%) 0.5
Lesions treated 1.43 0.8 1.43 0.7 0.9
Total stent length 33.5 23 33.2 24 0.7
Stent diameter, mm 2.98 0.4 2.99 0.4 0.5
Dual therapy, months 11.4 1.8 11.5 1.7 0.2
Lesions n  1,859 n  1,865
Total occlusion 71 (3.8%) 75 (4%) 0.8
Restenosis 19 (1%) 26 (1.4%) 0.2
Bifurcation 256 (13.8%) 250 (13.4%) 0.7
Calciﬁed 375 (20.2%) 379 (20.3%) 0.9Abbreviations as in Table 1.
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915tent apposition, and persistent local hypersensibility reac-
ions possibly due to residual polymer (16).
Second-generation DES are made of new polymers and
rugs. Pre-clinical studies show a promising faster endothe-
ialization with EES, compared with SES or PES (17). In
ddition, the ultrasonographic analysis of patients with EES
n the SPIRIT III (Clinical Evaluation of the Xience V
verolimus Eluting Coronary Stent System in the Treat-
ent of Patients with de novo Native Coronary Artery
esions) trials (11) showed only a 1.1% of late acquired
ncomplete stent apposition. The ultrasonographic studies
erformed in subgroups of patients in ENDEAVOR II
Randomized Controlled Trial to Evaluate the Safety and
fficacy of the Medtronic AVE ABT-578 Eluting Driver
oronary Stent in De Novo Native Coronary Artery Le-
ions) and III (Randomized Controlled Trial of the
edtronic Endeavor Drug-Eluting Coronary Stent System
ersus the Cypher Sirolimus-Eluting Coronary Stent Sys-
em in De Novo Native Coronary Artery Lesions) trials
ith ZES yielded a complete and uniform intimal coverage
ithout late acquired incomplete stent apposition (18).
Figure 2. Thrombosis Incidence in Matched Groups
Incidence of stent thrombosis in matched groups: (A) deﬁnite stent thrombosi
probable  possible stent thrombosis (p  0.4). The blue lines are for the zo
data. Abbreviations as in Figure 1.
Table 4. Cumulative Incidences of Stent Thrombosis in Propensity Score
Matched Groups
Definite Def.  Prob. Def.  Prob.  Poss.
ZES EES ZES EES ZES EES
1 month 0.6 0.3 1.0 0.6 1.0 0.6
1 yr 0.9 0.85 1.5 1.5 2.1 1.6
2 yrs 1.0 1.1 1.7 1.9 2.6 2.35
p 0.8 p 0.9 p 0.4Abbreviations as in Tables 1 and 2.hese latter results have been confirmed using optical
oherence tomography in the ODESSA (Optical Coher-
nce Tomography for DES Safety) trial (19). Despite of
hese findings, these stents have already been evaluated in
ifferent clinical trials showing disparate results regarding
afety comparison with first-generation DES (7–14). Nev-
rtheless, the clinical trials carried out to date have not been
owerful enough to point out differences in thrombosis rates
etween stent models.
However, EES and ZES significantly differ in their
erformance. Late lumen loss with EES is very low, around
.15 mm (10,11), whereas it is greater with ZES, 0.6 mm
7,8). Hence, this different efficacy profile may potentially
ranslate into safety issues.
hrombosis of ZES in trials. Combined analysis of
NDEAVOR I, II, and III (Multicenter Evaluation of
BT-578 Elution From a Phosphorylcholine-Coated
0.8); (B) deﬁnite  probable stent thrombosis (p  0.9); (C) deﬁnite 
us-eluting stent data, and the brown lines are for everolimus-eluting stent
Table 5. Predictors of Stent Thrombosis
HR 95% CI p Value
Univariate analysis
Bifurcations 1.75 1.04–2.9 0.03
EF 0.97 0.95–0.99 0.005
HBP 1.8 1.06–3.0 0.03
Stent diameter 0.4 0.2–0.91 0.03
RF 2.03 1.01–3.9 0.04
Age 1.02 1.003–1.04 0.02
Multivariate analysis
Bifurcations 2.1 1.14–3.7 0.02
EF 0.97 0.95–0.99 0.008
Stent diameter 0.37 0.17–0.81 0.01s (p 
tarolimCI confidence interval; HR hazard ratio; RF renal failure; other abbreviations as in Table 1.
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916tent) trials with a total of 1,317 ZES treated patients,
btained an absence of thrombosis after 14 days of deploy-
ent and up to 2 years, being the final thrombosis rate of
nly 0.3% (20). However, these results diverge from those
ound in ENDEAVOR IV (Randomized, Controlled Trial
f the Medtronic Endeavor Drug-Eluting Coronary Stent
ystem Versus the Taxus Paclitaxel-Eluting Coronary Stent
ystem in De Novo Native Coronary Artery Lesions) (9)
nd SORT OUT III (Comparison of Zotarolimus-Eluting
tents and Sirolimus-Eluting Stents in Patients With Cor-
Figure 3. Thrombosis Incidence and Dual Antiplatelet Therapy Duration
(A) Incidence of deﬁnite  probable stent thrombosis in cases with dual
antiplatelet therapy prescribed for 12 months (p  0.5). The blue line is
for the zotarolimus-eluting stent data, and the brown line is for everoli-
mus-eluting stent data. (B) Incidence of deﬁnite  probable stent throm-
bosis in cases with dual antiplatelet therapy prescribed for 12 months or 6
months (p  0.19). The blue line is for 6-month data, and the brown line
is for 12-month data. Abbreviations as in Figure 1.nary Artery Disease) (14) trials. In the first study (9),nvolving 773 ZES- and 775 PES-treated patients, 1-year
efinite plus probable thrombosis rate was 0.1% with PES
nd 1% with ZES. In the SORT OUT III (14) study,
efinite thrombosis incidence at 18 months was 1.2% in
,162 ZES-treated patients and 0.6% in the 1,170 SES-
reated patients.
hrombosis of EES in trials. In the SPIRIT III study, the
69 patients treated with EES showed a global stent
hrombosis incidence similar to that of 332 PES-treated
atients. However, a trend toward lower late thrombosis
ate was noted in EES-treated patients after the first year
nd in those in whom thienopyridine withdrawal took place
month after the procedure (12).
Figure 4. Thrombosis Incidence in Patients With Bifurcations Treated
(A) Incidence of deﬁnite  probable stent thrombosis in cases with and with-
out bifurcations treated (p  0.019). The blue line indicates no bifurcations,
and the brown line indicates bifurcations. (B) Incidence of deﬁnite  proba-
ble stent thrombosis in bifurcations of both stent groups (p  0.017). The
blue line is for the zotarolimus-eluting stent data, and the brown line is for
everolimus-eluting stent data. Abbreviations as in Figure 1.
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917In the pooled SPIRIT II and III analysis (21), late
efinite plus probable thrombosis rate at 1 year was 0.8% for
oth the 892 EES-treated patients and the 410 PES-treated
atients. The larger SPIRIT IV study (22), not published
et, has shown in 2,459 EES-treated patients a definite plus
robable thrombosis rate at 1 year of 0.29% compared with
.06% in PE-treated patients.
The COMPARE (Second-Generation Everolimus-
luting and Paclitaxel-Eluting Stents in Real-Life Practice)
rial (13), which aimed to compare EES versus PES, found
-year thrombosis rate to be significantly lower with EES.
his difference was due to a lower subacute thrombosis rate,
hereas late thrombosis was similar in both groups (13).
hrombosis in second-generation DES registries. After these
nconclusive results and taking into account the already
entioned limitations of clinical trials, it becomes necessary
o evaluate the real practice outcomes including long-term
ollow-up to assess whether second-generation DES throm-
osis rate remains similar to that of first-generation DES or
f they differ. Moreover, it is essential to find out whether
ate thrombosis rate is comparable in the 2 currently
vailable second-generation DES, taking into account their
ifferent behaviors (lower late lumen loss with EES).
To assess these questions, the Rotterdam team has
eported its real practice experience with EES up to 6
onths. Six-month outcomes in 649 EES-treated patients
ere compared with cohorts of patients treated with either
are-metal stents, PES, or SES (23). They found no
tatistically significant differences in thrombosis rates; of
ote, no thromboses were detected in EES-treated patients
fter 1 month. However, no conclusions regarding the safety
f the stent profile could be done as the number of patients
as relatively small. In addition, clinical follow-up was
Age > 75 years
Male
HBP
Diabetes
MI
EF<45%
Stent diameter < 3 mm
Total stent length > 50 mm
Bifurcations
1.78 (0.6-5.2) 
1.36 (0.67-2.8) 
1.06 (0.5-2.2) 
1.07 (0.36-3.2) 
0.55 (0.09-3.3) 
1.66 (0.4-6.8) 
1.17 (0.47-2.9) 
0.5 (0.12-1.9) 
5.4 (1.2-25) 
HR 0.1 1 10
ZES better       EES better
Figure 5. Forest Plot EES Versus ZES
Differences in thrombosis risk between EES and ZES in clinical and lesion
subsets within matched groups. Abbreviations as in Figure 1.imited at 6 months. pThe E-Five Registry (a prospective registry) involved
,314 ZES-treated patients in 118 centers. In this registry,
ith a follow-up limited to 1 year, definite/probable stent
hrombosis rate was 1.1% (24). However, it was unclear
hether patient inclusion was consecutive. In fact, the
umber of lesions treated per patient was only 1.2 (in our
egistry this was 1.45, which correlates better with numbers
btained in nonselective global series).
STROFA-2 registry. Our ESTROFA-2 registry aimed to
valuate definite plus probable and possible stent thrombosis
ates for up to 2 years in an ample “all comers” group of
onsecutive cases treated with EES and ZES, with no
xclusion criteria.
Clinical and lesional features revealed a standard real-
ractice profile. Being a registry, ZES and EES groups
iffer in some characteristics: ZES were used more often in
cute coronary syndromes (maybe due to a pre-conceived
igher safety profile), whereas EES, were more frequently
sed in diabetics and restenotic lesions (perhaps as the result
f their lower late lumen loss).
Thrombosis rates following the different definitions were
ow and comparable between groups. This lack of difference
as confirmed also after matching propensity score analysis.
efinite thrombosis rate at 2 years was 1% with an incre-
ent between the first and second year of 0.2% to 0.25%.
Comparing these results with those obtained in first-
eneration DES registries is intricate as a great amount of
oncontrollable factors could be playing a role. However,
efinite thrombosis rate at 1 year in first-generation DES
egistries was around 1.2% to 1.7% with a thrombosis
ncrement after the first year of 0.4% to 0.6% (2–6).
ifferent issues could help to explain this difference apart
rom those intrinsic to DES. A better selection of patients
or DES took place after 2006 because of the “late throm-
osis DES crisis,” but certainly clinical profile remains
omparable and DES penetration (at least in Spain) has
een even higher in ESTROFA-2 inclusion period (55% to
0%) than in ESTROFA inclusion period (35% to 40%).
Therapeutic compliance and dual antiplatelet treatment
xtent could also have increased. Indeed, mean time of dual
ntiplatelet treatment in ESTROFA registry was 8 months
ompared with almost 12 months in ESTROFA-2 (5). In
STROFA, up to 31.6% of definite thromboses were
elated to nontreatment compliance compared with 15% in
he present registry. This statement could be linked to a
etter compliance but also to a greater susceptibility of
rst-generation DES to antiplatelet treatment withdrawal.
he lack of specific evaluation of antiplatelet treatment
ompliance in these registries remains a caveat that should
e addressed in future, dedicated registries.
Regarding duration of dual antiplatelet treatment, most
atients in this study were instructed to continue it during
2 months. There was a small group with only 6-month
rescriptions. These patients were more frequently found in
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918he ZES group, most probably due to an understood high
afety profile. This group showed a nonsignificant trend
oward more thrombosis but, paradoxically, it was concen-
rated in the early stage. These findings suggest that this
roup could be conformed of patients with worse biological
onditions and more comorbidities that could lead to a
reater bleeding risk. Anyway, this variable did not come
ut as a predictor in the analysis.
Finally, thrombosis predictors detected in our analysis—
ower ejection fraction, lower stent diameter, and bifurca-
ions—had already been documented in other studies (2,3).
ifurcations have been analyzed in depth, as it was the only
ubset in which statistically significant differences regarding
hrombosis rates were observed in among second-generation
ES. Thrombosis rates in ZES-treated patients with bi-
urcation lesions were greater in both early and late stages.
se of ZES was an independent predictor of thrombosis in
he subgroup of patients with bifurcation lesions. The
eason for this could be explained by means of various
actors such as greater late lumen loss (favoring a restenosis
eading to a prothrombotic condition) and different plat-
orm design. Anyway, the reason remains unknown and
hese findings warrant further research.
tudy limitations. Being a registry implies observational and
onrandomized findings. Stents were assigned by the oper-
tor, and even with matching propensity score analysis,
here remain underlying variables that could play a role
n the results. That is why the comparison of both groups
as to be done by taking into account this limitation.
oreover, the different outcome of the bifurcational sub-
roups in both stent groups should be considered cautiously.
Using these results to obtain conclusions regarding
econd-generation DES safety as opposed to first-
eneration DES is even tougher. This does not nullify the
act that the second-generation DES safety profile in the
ettings in which they are used nowadays is better than
he profile revealed by first-generation DES in the previous
ears.
Antiplatelet treatment compliance was not possible to
nalyze. This would have required a very frequent and
xhaustive monitoring of every single patient, which was
eyond the potential of the registry. The antiplatelet therapy
essation would probably be a major determinant of throm-
osis, though we do not know how many patients without
hrombosis had discontinuation of therapy in the study
eriod.
Patients with previous percutaneous coronary interven-
ion procedures (whatever the stent type) were included.
his fact could be a problem in the adjudication of a
robable thrombosis event; however, every single case of
hrombosis was carefully analyzed, and we did not have such
conflictive case. Last but not least, the earlier introduction
f ZES in the Spanish market implies a longer follow-up of
hese patients than for EES-treated patients.onclusions
n a real practice setting with frequent off-label indications,
he incidence of thrombosis at 2 years with ZES and EES
as low and quite similar. The incidence increase of definite
hrombosis between the first and second years was 0.2% to
.25%, which is lower than the rates previously reported for
ES and PES (0.4% to 0.6%). This finding suggests that the
ncidence of very late thrombosis could be lower for second-
eneration DES. In the subset of bifurcations, the use of
ES could be associated with a higher risk of thrombosis,
hough this finding warrants further research.
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